Mednet Reports
MEDICAL FRONTIERS - XXI World Congress of Neurology
Early Intervention and a Tailored Approach: Opportunity for Improved Disease Control in the Management of Relapsing-Remitting Multiple Sclerosis
Vienna, Austria / September 21-26, 2013
Vienna - Of all patients diagnosed with multiple sclerosis (MS), 90% will have relapsing-remitting multiple sclerosis (RRMS), the other 10% having a primary progressive form of the disease. Without treatment, approximately half of patients...
PRIORITY PRESS - 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Staying Ahead of the Resistance Curve: Current and Future Strategies for More Effective Infection Control
Denver, Colorado / September 10-13, 2013
Denver - Staying ahead of the resistance curve has never been more challenging in the management of acute and chronic infections. In the past few decades, there has been a remarkable increase in resistance to current antibiotics. As new...
PRIORITY PRESS - European Respiratory Society (ERS) Annual Congress 2013
Emerging Bronchodilation Strategies for Improved COPD Control and Progression
Barcelona, Spain / September 7-11, 2013
Barcelona - In the treatment algorithm for chronic obstructive pulmonary disease (COPD), the early combination of bronchodilators is expected to be moved forward in guideline-based treatment. In the GOLD (Global Initiative for Chronic...
PRIORITY PRESS - European Respiratory Society (ERS) Annual Congress 2013
COPD Moves Toward Individualization of Care: Based on Need to Maximize Treatment Options
Barcelona, Spain / September 7-11, 2013
Barcelona - Based on a survey presented as a latebreaking presentation at the 2013 ERS, almost all specialists in chronic obstructive pulmonary disease (COPD) are aware of the GOLD (Global Initiative for Chronic Obstructive Lung Disease)...
MEDICAL FRONTIERS - European Respiratory Society (ERS) Annual Congress 2013
New Treatment Options in Pulmonary Arterial Hypertension Appear to Move Treatment Goals Beyond Symptom Control
Barcelona, Spain / September 7-11, 2013
Barcelona - New data presented at the ERS 2013 from trials published just weeks before the meeting was convened, document a paradigm shift in the treatment of pulmonary hypertension. In pulmonary arterial hypertension, the benefit of a new...
PRIORITY PRESS - 35th Annual Congress of the European Society of Cardiology (ESC)
Phase III Trials in Pulmonary Arterial Hypertension Focus on Clinical Events Rather Than Symptom Control
Amsterdam, Netherlands / August 31-September 4, 2013
Amsterdam - In pulmonary arterial hypertension (PAH), trials are being increasingly designed to evaluate protection against disease progression rather than symptom control alone, according to data presented at the 2013 ESC. The trial data...
PRIORITY PRESS - 35th Annual Congress of the European Society of Cardiology (ESC)
Vascular Outcomes Trials Confirm Safety of DPP-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Amsterdam, Netherlands / August 31-September 4, 2013
Amsterdam - Both of the first two trials in a series to confirm the cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors met their primary end point. Although there are important differences in the design and information...
MEDI-NEWS - Based on Lancet 2013;381(9869):825-35.
Invasive Meningococcal Disease in Infants: Immunogenicity and Safety of a Novel Multi-Component Serogroup B Vaccine
Serogroup B is now the dominant cause of invasive meningococcal disease (IMD) in Canada where it disproportionally affects infants. This underscores the importance of having an effective vaccine for this vulnerable age group. A...
PRIORITY PRESS - 8th World Congress of Melanoma
New Advances in the Treatment of Basal Cell Carcinoma: Targeting the Hedgehog Signaling Pathway
Hamburg, Germany / July 17-20, 2013
Hamburg - Until recently, treatment options for advanced basal cell carcinoma (BCC) were limited and suboptimal. Research into novel therapeutic targets identified mutations in the hedgehog signaling pathway as a possible cause of new...
PRIORITY PRESS - XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH)/ 59th Annual Scientific and Standardization Committee (SSC) Meeting
Potential for Advances in the Treatment of Hemophilia A
Amsterdam, The Netherlands / June 29-July 4, 2013
Amsterdam - Current treatment for patients with hemophilia A, the most common hereditary coagulation disorder, involves intravenous injection of human factor VIII given on demand in response to a bleeding event or as a prophylactic therapy....
